Trial shows pembrolizumab performs better than chemotherapy in second line treatment of advanced oesophageal cancer

04:33 EST 16 Jan 2019 | ecancermedicalscience

Announced today were the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating pembrolizumab, an anti-PD-1 therapy, as monotherapy for the second-line treatment of advanced or metastatic oesophageal or oesophagogastric junction...

More From BioPortfolio on "Trial shows pembrolizumab performs better than chemotherapy in second line treatment of advanced oesophageal cancer"